FDA joins EU and Japan in deciding if Abecma may treat RRMM earlier
The U.S. Food and Drug Administration (FDA) has agreed to review an application that, if approved, would allow the cell therapy Abecma (idecabtagene…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
Marisa Wexler, MS, senior science writer —
Articles by Marisa Wexler
CAR T-cell therapy, CB-011, on FDA fast track for hard-to-treat myeloma
The U.S. Food and Drug Administration (FDA) has given a fast track designation to CB-011, an experimental CAR T-cell therapy being developed by…
New mouse models may accelerate multiple myeloma research
More than a dozen new mouse models of multiple myeloma, which researchers hope will advance understanding and treating the disease, were described in a…
Fatty acid-binding proteins may be potential target for myeloma
Blocking the activity of a group of proteins called fatty acid-binding proteins (FABPs) may be a useful treatment strategy for multiple myeloma, a new…
FDA Asked to Approve Talquetamab for Hard-to-treat Multiple Myeloma
Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) asking that talquetamab be approved to treat relapsed or refractory…
Real-world Study Supports Blenrep for Hard-to-treat RRMM
The efficacy and safety of Blenrep (belantamab mafodotin) as a treatment for relapsed/refractory multiple myeloma (RRMM) in a real-world setting is similar to what…
OCEAN Trial Fails to Support Pepaxto for RRMM, FDA Panel Finds
An advisory panel to the U.S. Food and Drug Administration (FDA) has overwhelmingly decided that the Phase 3 OCEAN clinical trial did not provide sufficient…
Teclistamab Plus Darzalex Found to Ease Cancer Burden in Phase 1 Trial
A combination of the investigational therapy teclistamab and the approved medication Darzalex (daratumumab) reduced the cancer burden for most people with relapsed or refractory…
Nexpovio Triple Combo Approved as Myeloma Treatment in Europe
The European Commission has granted full approval to a triple combination therapy of Nexpovio (selinexor) — sold in the U.S. as Xpovio —  to treat…
Tecvayli Recommended for Conditional Approval in Europe
A branch of the European Medicines Agency (EMA) has recommended that Janssen’s investigational therapy Tecvayli (teclistamab) be granted conditional marketing authorization for adults with…
